Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How much is mebendazole?
When will there be a generic loreev available?
Somatuline depot patent expiry date?
Somatuline generic name?
Xenazine current manufacturer 2025?

Acalabrutinib pharmaceutical brand?

See the DrugPatentWatch profile for Acalabrutinib

Calquence.

Calquence (acalabrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by AstraZeneca, approved for mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (and used in other B-cell malignancies as indicated). Would you like more details on indications, dosing, or interactions?



Other Questions About Acalabrutinib :

Acalabrutinib fda approval october 2017 calquence? Acalabrutinib? Acalabrutinib calquence fda approval date? Acalabrutinib fda approval history drugs com? Acalabrutinib fda approval date calquence 2017? Acalabrutinib approval date? Acalabrutinib market?